Skip to main content
Clinical Trials/CTRI/2025/07/091068
CTRI/2025/07/091068
Not yet recruiting
Phase 3 4

"A Comparative Evaluation of Injectable Platelet-Rich Fibrin (i-PRF) With and Without Amoxicillin in the Treatment of Chronic Periodontitis: A Randomized Controlled Trial"

Priyanka yadav1 site in 1 country40 target enrollmentStarted: September 19, 2025Last updated:

Overview

Phase
Phase 3 4
Status
Not yet recruiting
Sponsor
Priyanka yadav
Enrollment
40
Locations
1
Primary Endpoint
To evaluate the efficacy of amoxicillin incorporated I-PRF as local drug delivery for the treatment.

Overview

Brief Summary

To achieve the desirable accomplishments, there we are attempting to evaluate the clinical efficacy of injectable Platelet-Rich Fibrin (i-PRF) with and without amoxicillin as an adjunct to scaling and root planing (SRP) in the management of chronic periodontitis. A total of eligible participants will be randomly allocated into two groups: the test group will receive SRP followed by subgingival injection of amoxicillin-loaded i-PRF, while the control group will receive SRP followed by injection of drug-free i-PRF. i-PRF is prepared from autologous blood using a low-speed centrifugation protocol and injected into periodontal pockets more than 5 mm and adjacent interdental papillae in a single treatment session. The study aims to assess and compare clinical periodontal parameters such as probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque index (PI) at baseline and subsequent follow-ups. The objective is to determine whether the addition of amoxicillin to i-PRF enhances periodontal healing outcomes compared to i-PRF alone.

Study Design

Study Type
Interventional
Allocation
Coin toss, Lottery, toss of dice, shuffling cards etc
Masking
Participant and Outcome Assessor Blinded

Eligibility Criteria

Ages
25.00 Year(s) to 50.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 1.Patient diagnosed with chronic periodontitis o Patients having periodontal pockets of more than 5 mm
  • Patient with clinical attachment loss more than 2 mm 3.Age group between 25- 50 years.
  • Patients with good general health, without any history of systemic disease or under medication
  • Patient ready to give written informed consent.

Exclusion Criteria

  • Medically compromised patient.
  • o Patient on antimicrobial therapy
  • Smokers and smokeless tobacco users.
  • Patients showing unacceptable oral hygiene during evaluation.
  • Patient who received periodontal therapy in the past 6 months.
  • 5.Pregnant women and lactating mothers.

Outcomes

Primary Outcomes

To evaluate the efficacy of amoxicillin incorporated I-PRF as local drug delivery for the treatment.

Time Frame: At base line, 1month, 3month

Secondary Outcomes

  • I.Assessment of gingival index and plaque index before and after placement of amoxicillin incorporated I-PRF as local drug delivery.(II.Assessment of periodontal pocket depth (PPD) and clinical attachment index (CAL) before and after index before and after placement of amoxicillin incorporate I-PRF .)

Investigators

Sponsor
Priyanka yadav
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Priyanka Yadav

faculty of dental sciences IMS, BHU

Study Sites (1)

Loading locations...

Similar Trials